Loading…
Trial demonstrated significant reduction in alcohol-related symptoms.
Quantum BioPharma Ltd. announced on February 04, 2025 Quantum Biopharma announced the success of its unbuzzd™ clinical trial, which demonstrated that the dietary supplement dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration, and reduces symptoms of intoxication, impairment, and hangover, with results compared to placebo.
67 percent reduction in headache severity. The announcement cited more than 40 percent faster.
Quantum Biopharma Ltd. has a free float of 3,474,500 shares and 3,817,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.